- Home
- PETZ vs CDIO Comparison
PETZ vs CDIO Comparison
Compare PETZ & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- CDIO
- Stock Information
- Founded
- PETZ 2002
- CDIO 2017
- Country
- PETZ China
- CDIO United States
- Employees
- PETZ N/A
- CDIO N/A
- Industry
- PETZ Steel/Iron Ore
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- PETZ Industrials
- CDIO Health Care
- Exchange
- PETZ Nasdaq
- CDIO Nasdaq
- Market Cap
- PETZ 12.2M
- CDIO 12.3M
- IPO Year
- PETZ 2017
- CDIO N/A
- Fundamental
- Price
- PETZ $1.16
- CDIO $0.53
- Analyst Decision
- PETZ
- CDIO Buy
- Analyst Count
- PETZ 0
- CDIO 1
- Target Price
- PETZ N/A
- CDIO $2.00
- AVG Volume (30 Days)
- PETZ 16.7K
- CDIO 2.5M
- Earning Date
- PETZ 12-17-2024
- CDIO 11-13-2024
- Dividend Yield
- PETZ N/A
- CDIO N/A
- EPS Growth
- PETZ N/A
- CDIO N/A
- EPS
- PETZ N/A
- CDIO N/A
- Revenue
- PETZ $3,278,453.00
- CDIO $35,688.00
- Revenue This Year
- PETZ N/A
- CDIO $2,081.66
- Revenue Next Year
- PETZ N/A
- CDIO $43.84
- P/E Ratio
- PETZ N/A
- CDIO N/A
- Revenue Growth
- PETZ 2.46
- CDIO 180.90
- 52 Week Low
- PETZ $0.98
- CDIO $0.19
- 52 Week High
- PETZ $1.74
- CDIO $2.40
- Technical
- Relative Strength Index (RSI)
- PETZ 46.18
- CDIO 38.70
- Support Level
- PETZ $1.18
- CDIO $0.49
- Resistance Level
- PETZ $1.24
- CDIO $0.62
- Average True Range (ATR)
- PETZ 0.09
- CDIO 0.11
- MACD
- PETZ -0.01
- CDIO -0.06
- Stochastic Oscillator
- PETZ 11.43
- CDIO 8.34
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.